Emi Kawakita

Dr. Emi Kawakita

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EKEmi Kawakita
Emi Kawakita
DKDaisuke Koya
Daisuke Koya
KKKeizo Kanasaki
Keizo Kanasaki
DPP-4/CD26, a membrane-bound glycoprotein, is ubiquitously expressed and has diverse biological functions. Because of its enzymatic action, such as the degradation of incretin hormones, DPP-4/CD26 is recognized as the significant therapeutic target for type 2 diabetes (T2DM); DPP-4 inhibitors have been used as an anti-diabetic agent for a decade. The safety profile of DPP-4 inhibitors for a cardiovascular event in T2DM patients has been widely analyzed; however, a clear association between DPP-4 inhibitors and tumor biology is not yet established. Previous preclinical studies reported that DPP-4 suppression would impact tumor progression processes. With regard to this finding, we have shown that the DPP-4 inhibitor induces breast cancer metastasis and chemoresistance via an increase in its substrate C-X-C motif chemokine 12, and the consequent induction of epithelial-mesenchymal transition in the tumor. DPP-4/CD26 plays diverse pivotal roles beyond blood glucose control; thus, DPP-4 inhibitors can potentially impact cancer-bearing T2DM patients either favorably or unfavorably. In this review, we primarily focus on the possible undesirable effect of DPP-4 inhibition on tumor biology. Clinicians should note that the safety of DPP-4 inhibitors for diabetic patients with an existing cancer is an unresolved issue, and further mechanistic analysis is essential in this field.

12 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
EKEmi Kawakita
Emi Kawakita
FYFan Yang
Fan Yang
SSSen Shi
Sen Shi
YTYuta Takagaki
Yuta Takagaki
DKDaisuke Koya
Daisuke Koya
KKKeizo Kanasaki
Keizo Kanasaki
Autophagy plays a complex role in breast cancer cell survival, metastasis, and chemotherapeutic resistance. Dipeptidyl peptidase (DPP)-4, a therapeutic target for type 2 diabetes mellitus, is also involved in autophagic flux. The potential influence of DPP-4 suppression on cancer biology remains unknown. Here, we report that DPP-4 deficiency promotes breast cancer cell survival via the induction of autophagy by the C-X-C motif chemokine 12 (CXCL12)/C-X-C receptor 4 (CXCR4)/mammalian target of rapamycin (mTOR)/hypoxia inducible factor (HIF)-1α axis. DPP-4 knockdown and DPP-4 inhibitor KR62436 (KR) treatment both increased the levels of LC3II and HIF-1α in cultured human breast and mouse mammary cancer cells. The KR-induced autophagic phenotype in cancer cells was inhibited by treatment with the CXCR4 inhibitor AMD3100 and rapamycin. HIF-1α knockdown also suppressed breast cancer autophagy induced by KR. The autophagy inhibitor 3-methyladenine significantly blocked the KR-mediated suppression of cleaved caspase-3 levels and apoptosis in breast cancer cell lines. Finally, we found that the metformin-induced apoptosis of DPP-4-deficient 4T1 mammary cancer cells was associated with the suppression of autophagy. Our findings identify a novel role for DPP-4 inhibition in the promotion of breast cancer survival by inducing CXCL12/CXCR4/mTOR/HIF-1α axis-dependent autophagy. Metformin is a potential drug that counteracts the breast cancer cell survival system.

22 January 2025 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
SIShin‐Ichiro Ishihara
Shin‐Ichiro Ishihara
IKImrul Kayes
Imrul Kayes
HMHirofumi Makino
Hirofumi Makino
HMHiroaki Matsuda
Hiroaki Matsuda
AKAsako Kumagai
Asako Kumagai
KKKeizo Kanasaki
Keizo Kanasaki
Aim/Introduction: Senescence is a key driver of age‐related kidney dysfunction, including diabetic kidney disease. Oxidative stress activates cellular senescence, induces abnormal glycolysis, and is associated with pyruvate kinase muscle isoform 2 (PKM2) dysfunction; however, the mechanisms linking PK activation to cellular senescence have not been elucidated. We hypothesized that PKM2 activation by TEPP‐46 could suppress oxidative stress‐induced renal tubular cell injury and cellular senescence.Materials and Methods: To investigate the effects of PKM2 activation on oxidative stress‐induced cellular senescence, we conducted β‐galactosidase staining and western blot analysis on human primary renal tubular cells (pRPTECs) treated with hydrogen peroxide with or without TEPP‐46. IL‐6 levels and glycolytic flux were measured. Cell viability and apoptosis were assessed via the MTS assay and caspase 3 cleavage. For in vivo experiments, we utilized CD‐1db/db mice, a fibrotic type 2 diabetes model, which exhibit kidney fibrosis. After 4 weeks of TEPP‐46 intervention, kidney fibrosis and the expression of senescence markers were analyzed.Results: In pRPTECs, hydrogen peroxide increased the number of β‐galactosidase‐positive cells, the expression of senescence markers (p16, p21, p53), and p38 phosphorylation; co‐incubation with TEPP‐46 suppressed these alterations. Hydrogen peroxide reduced cell viability, induced apoptosis, mesenchymal alterations, and increased lactate production and IL‐6 secretion; co‐incubation with TEPP‐46 or a p38 inhibitor mitigated these effects. In CD‐1db/db mice, TEPP‐46 intervention suppressed apoptosis, fibrosis, and tended to reduce the levels of senescence‐associated molecules in the kidney.Conclusions: PKM2 activation could be a molecular target for protection against senescence‐associated organ damage, including diabetic kidney disease.

8 March 2024 in Journal of Diabetes Investigation
Verified
Journal Article
Open access
EKEmi Kawakita
Emi Kawakita
KKKeizo Kanasaki
Keizo Kanasaki
The association of type 2 diabetes with certain cancer risk has been of great interest for years. However, the effect of diabetic medications on cancer development is not fully understood. Prospective clinical trials have not elucidated the long‐term influence of hypoglycemic drugs on cancer incidence and the safety for cancer‐bearing patients with diabetes, whereas numerous preclinical studies have shown that antidiabetic drugs could have an impact on carcinogenesis processes beyond the glycemic control effect. Because there is no evidence of the safety profile of antidiabetic agents on cancer biology, careful consideration would be required when prescribing any medicines to patients with diabetes and existing tumor. In this review, we discuss the potential influence of each diabetes therapy in cancer ‘initiation’, ‘promotion’ and ‘progression’.

12 December 2024 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SFSara Amelia Ferdaus
Sara Amelia Ferdaus
HOHiroki Ohara
Hiroki Ohara
HMHiroyuki Matsuo
Hiroyuki Matsuo
KKKohei Kawakami
Kohei Kawakami
FTFumihiko Takeuchi
Fumihiko Takeuchi
KKKeizo Kanasaki
Keizo Kanasaki